Adenosine transporter Inhibitors
1 drugsAbout Adenosine transporter
Adenosine transporters regulate extracellular adenosine concentration, modulating adenosine signaling by controlling cellular uptake and release. These membrane proteins, also known as nucleoside transporters, influence diverse physiological processes.
Currently, there is no genetic evidence directly linking adenosine transporters to specific diseases. However, modulating adenosine levels via these transporters holds therapeutic potential, particularly in the cardiovascular system.
Adenosine transporters are targeted by one FDA-approved drug, ASPIRIN AND DIPYRIDAMOLE, a small molecule used in cardiovascular medicine. This drug was first approved in 2009 and is marketed by AMNEAL PHARMS.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Antiplatelet Drugs with only 4 trials.
- phase3 represents biological uncertainty with 59% completion.
Top Adenosine transporter Drugs
AMNEAL PHARMS is the only company with an approved drug targeting adenosine transporters.
Low competition may indicate a niche market or high entry barriers; assess market potential before investing heavily.
Adenosine transporter Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Adenosine transporter, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies and potentially improve efficacy.
Adenosine transporter Clinical Trials 513 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 68 | 57 | 3 | 6 | 95% |
| Phase 2 | 104 | 66 | 17 | 20 | 80% |
| Phase 3 | 125 | 54 | 22 | 49 | 71% |
| Phase 4 | 216 | 123 | 28 | 63 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Adenosine transporter Drug Approval Timeline (2009 - 2009)
The first and only drug targeting adenosine transporters was approved in 2009.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies; investigate reasons for stagnation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 6 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 338 clinical trials targeting Adenosine transporter.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities